Relmada Therapeutics is advancing NDV-01, a novel intravesical therapy for NMIBC, into phase 3 clinical trials, with Max Kates, M.D., joining their advisory board. NDV-01 combines gemcitabine and ...
Azitra, Inc. (NYSE:AZTR) reported third quarter 2025 results in a November 12th press release and provided a business update. Since our previous quarterly update in August, Azitra has announced that ...
The agency has faced blowback from business leaders and Republicans over plans to end the popular energy efficiency program. By Maxine Joselow and Lisa Friedman Reporting from Washington Lee Zeldin, ...
BRANFORD, Conn., Oct. 20, 2025 /PRNewswire/ -- Azitra, Inc. (AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
Photo Credit: IPhone apps for OYO, Airbnb Trivago, Booking.com, Expedia, Agoda, Hotels.com and Hostelworld. Adobe Stock / Koshiro K On the competitive disadvantage front, Dan Wasiolek, senior equity ...
VER-01 significantly reduced pain intensity in chronic low back pain compared with placebo, with effects sustained during 12 months of treatment. VER-01 was generally well tolerated, with no signs of ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Genfit SA ( (GNFT)) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback